← All trials
NCT04981561
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 9, 2016
- Primary completion
- Dec 21, 2017
- Completion date
- Dec 21, 2017
- First posted
- Jul 29, 2021
- Last posted
- Jul 29, 2021
- Enrollment
- 68
- Arms / groups
- 10 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Gate Neurosciences, IncLead sponsor
- Gate Neurosciences, IncSponsor investigator
- Gate Neurosciences, IncStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.